Content
Quantexa News
09/15
Short Interest in Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Rises By 115.7%
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 739...
Quantexa News
09/15
Short Interest in Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Rises By 115.7%
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 739,700 share...
Quantexa News
09/15
Short Interest in Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Rises By 115.7%
Monogram Orthopaedics, Inc. ( – ) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 739,700 shares, an increase o...
Quantexa News
09/15
Short Interest in Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Rises By 115.7%
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 7...
Quantexa News
09/15
Short Interest in Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Expands By 115.7%
NASDAQ:MGRM – Get Free Report ) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 739,700 shares, a growth of 115.7% from the August 15th tota...
Quantexa News
09/15
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Update
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 739,700 shares, an in...
Quantexa News
09/15
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Growth in Short Interest
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling...
Yahoo Finance Community
09/16
Comment
It looks like Dealmaker or Monogram was hacked with respect to the new offering. I did my transactions on line through the web. The fishing text I got was to my phone. I have two calls into Monogram in the last 4 days and have not received a response. They were trying to get personal information including employer information. This has never happened to me before so I am extremely confident that the leak did not occur at my end....
Yahoo Finance Community
09/16
Comment
Inappropriate questions for offering. I purchased some shares and the transaction went through. I then got a text message stating Action May be required to finalize your Monogram Investment. The required questions included:1) what is your marital status? It includes Widowed as if that matters.2) how many dependents do you have? Again not material.3) What is your employment status?4) If you say employed, they want a job description, again not material?5) What is your employer's name? - again none of their business.6) What is your employer's address? Im not applying for credit or opening an account.7) How many years have you been employed by your current employer? - not applying for a mortgage.8) Is your investment being made jointly with a spouse or partner? None of your business. My money is my business9) Do you have any association with the financial industry? Are you prohibiting a broker from adding to …...
Yahoo Finance Community
09/19
Comment
Given that the Monogram is still in the early stages as a startup, having weekly or bi-weekly status updates would really help maintain trust and keep everyone engaged, especially since the company is currently relying on investors. Disappearing after one update may work for a well-established company with solid products, revenue, and a customer base. If we aim to reach that level, we need to prioritize consistent communication first....
Yahoo Finance Community
09/30
Comment
Do we think that "reduced surgery time" will be an impactful value-generative feature of the mBos TKA system? What do you all think? I would say, Absolutely, it would be a prominent benefit of the technology because that would mean a coalescence of many factors including precision, planning, registration and cutting, ALL aspects that make the mBos a very efficient and durable system. Excited to see the results of the trials 👍...
Yahoo Finance News
10/02
Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering
Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering Monogram Technologies Inc. Wed, Oct 2, 2024, 5:00 PM 5 min read In This Article: MGRM -0.40% AUSTIN, T...
Yahoo Finance News
10/02
Monogram Technologies Receives FDA Response for mBôs TKA System
Monogram Technologies Receives FDA Response for mBôs TKA System Monogram Technologies Inc. Wed, Oct 2, 2024, 3:00 PM 5 min read In This Article: MGRM -0.40% Company to Conduct Clinical Trial to Produc...
Yahoo Finance Community
10/02
Comment
"Company to Conduct Clinical Trials to Produce Additional Information Within 180 Days": Is the FDA requesting new clinical trial data, or are they asking for additional information ?Did we submit for clinical trials?: When did we submit the clinical trial data approval? and where ( India, US ) ?Also, could you share what the plan is from now until the end of the year? It would be helpful to understand the timeline and key milestones moving forward. This is quite disappointing, and it seems as though investors were misled, especially since it appears you were aware of the FDA's response beforehand....
Yahoo Finance News
10/03
CORRECTION FROM SOURCE: Monogram Technologies Issues Correction to Press Release Announcing it Received an FDA Response for its mBôs TKA System
CORRECTION FROM SOURCE: Monogram Technologies Issues Correction to Press Release Announcing it Received an FDA Response for its mBôs TKA System Monogram Technologies Inc. Thu, Oct 3, 2024, 5:35 AM 3 m...
Yahoo Finance Community
10/03
Comment
Monogram should release a clear statement about whether the FDA is requesting clinical trials or not, and provide a detailed explanation of the clarification. It’s not sensitive information like a state or national secret, so they should be transparent with stakeholders. Providing precise information will help reduce uncertainty and improve communication with investors and the public.Ben's actions raise serious concerns about transparency and investor communication. If this isn't considered misleading, then what is? The press release consistently stated they were working with an Indian company on clinical trials, yet they failed to disclose that they hadn't even applied for the necessary approvals to begin these trials. Can someone ask why this wasn’t done proactively and why this crucial information wasn’t shared with investors? Such omissions reflect poorly on the integrity of the company and its leadership....
Yahoo Finance Community
10/04
Comment
FDA is surely requesting safety data, possibly including hazards & precautions, equipment sanitation and upkeep, equipment parts change-out standards and, imaginably, operational efficacy in terms of cross-contamination avoidance (i.e. infection rate) and cleanliness. Remember, the FDA clearance is for achieving Equivalence, and there are plenty examples of robots with track record of clearances regarding safety for use as historical precedence--so the goal is obtaining like-degree performance and standards here--that will get us to approval and clearance....
Yahoo Finance Community
10/06
Comment
Monogram HAS NOT yet received approval for clinical trials in India for semi-active systems, and there are currently NO active trials happening in India for semi-active systems. They failed to mention this in any press release, leaving the situation unclear. I have no information about the deal with Shelby or why there were delays in the approval process. It seems confusing—how could Shelby proceed with clinical trials without Monogram securing the necessary approvals, which, based on the facts, were never planned in the first place?I also just received a response from Monogram stating that the FDA is now asking for clinical trial data. Here's Monogram exact response to my question: "The FDA is suggesting clinical trial data would be helpful, so we are moving forward with obtaining clearance to perform those trials."...
Votes:
2
0
Yahoo Finance Community
10/07
Comment
It has always been contingent on the FDA decision though, and it wasn't settled because the 510k application wasn't submitted until July 19th and this was announced on Aug 8th. Mr Sexson said when they submitted the application, they had many experts look at the 28K page application and its equivalence potential to other robots and gave their confidence in the likelihood of approval. Which as we Learn as of Sept 30, the FDA ended up issuing an AIR, and through their communications with MGRM suggested that clinical trial data may help in their decision thus giving the company 180-days to respond. Look up the First Quarter 2024 Update Call, timestamp 27:55 - 31:27 that outlines the question re: "... on why and how the FDA can, or needs to rely on an OUS clinical trial to help make a decision" Mr Sexson makes it very clear ~ even way …...
Yahoo Finance Community
10/07
Comment
Johnson and Johnson states that their VELYs digital surgery takes about an hour for the surgery so the comparison to 80 minutes for Stryker has been weakened in value. Also, the Johnson and Johnson system is being used for knees and hips. The only potential advantage I see for MGRM is that Johnson and Johnson is robot assisted, not fully robotic....
Yahoo Finance Community
10/07
Comment
The is frustrating. Prior releases from the company made it look like clinical trials were about to be started with Shalby. The latest updates state that approval for clinical trials has not been granted and that it is not expected for more than three months. I would agree with Bay that the prior announcements seem to be misleading and in no uncertain terms does the the term "forward looking statements" dismiss intentionally misleading statements. How is it taking another four to six months for approval after an announcement that potential candidates are being enrolled?Now it looks I should have taken my own advice and sold my existing shares at $3.75 when enrolled for the new offering at $2.25 instead of just adding to my position....
Yahoo Finance Community
10/08
Comment
Ben should resign . It feels like management is taking advantage of investors' money without accountability. Dr. Unis holds over 5 million shares and is comfortably based in New York, seemingly unconcerned about investor interests. Even if Monogram fails, he doesn’t stand to lose anything. Ben, meanwhile, sitting on 5+ million shares, lacks the leadership needed for a CEO and has failed multiple times. Monogram appears to be operating without strong leadership, and it might be time for Ben to consider stepping down.This kind of behavior raises serious concerns, especially when the company's future and investor money & trust are on the line....
Yahoo Finance Community
10/08
Comment
The company has hit every milestone in stride, and adjusts quickly to pressures of FDA and cost of business. Don't act like shorts aren't having their influence in the decline of stock pricing also. Probably even moreso of an impact than anything the company directly does....
Votes:
1
1
Yahoo Finance Community
10/08
Comment
If you want something positive go to the holders tab and observe that several big institutional investors have joined including Vanguard adn Blackrock. Just please stop stating that clinical trials have started and we can't see the results due to patient privacy when they haven't. Claiming that missed milestones have been met. That incomplete submissions are a good thing. That running out of cash 9 months early and having a fire sale of a secondary offering is good for investors that paid more than three times as much for their shares over a year ago....
Quantexa News
10/10
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 1.7% – Here's Why
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report )'s stock price was up 1.7% during mid-day trading on Wednesday . The company traded as high as $2.43 and last traded at $2.36. Approximatel...
Quantexa News
10/10
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 1.7% – Here's Why
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report )'s stock price was up 1.7% during mid-day trading on Wednesday . The company traded as high as $2.43 and last traded at $2.36. Approximatel...
Quantexa News
10/10
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 1.7% - Here's Why
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report)'s stock price was up 1.7% during mid-day trading on Wednesday . The company traded as high as $2.43 and last traded at $2.36. Approximately...
Yahoo Finance Community
10/11
Comment
Bay, there's something wrong with the person posting as Kimsotus. The statements are intentionally false beyond misleading. It's as though they are starting fights on this board to get people to respond in a way to get them kicked off. I decided to stop replying. You'll know if the clinical partner is any good if they keep the candidate list current and the robot/operating room ready by how soon actual trials start after approval if it ever happens. I sincerely hope it does as I have averaged down from $7.25 to below $4....
Quantexa News
10/12
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Large Drop in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 506,500 shares, a decrease of...
Quantexa News
10/12
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Update
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totall...
Quantexa News
10/12
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Large Drop in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 506,500 shares, a decrease of...
Quantexa News
10/12
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Large Drop in Short Interest
NASDAQ:MGRM – Get Free Report ) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 506,500 shares, a decrease of 26.5% from the September 15t...
Quantexa News
10/12
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Large Drop in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 506,500 shares, a decrease of...
Yahoo Finance News
10/16
Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024
Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024 Monogram Technologies Inc. Wed, Oct 16, 2024, 5:31 AM 4 min read In This Article: MGRM +3.91%...
Quantexa News
10/26
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Down 40.0% in October
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 30...
Quantexa News
10/26
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Down 40.0% in October
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 303,800 shares, a decrease of 40.0...
Yahoo Finance News
10/29
Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024
Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024 Monogram Technologies Inc. Tue, Oct 29, 2024, 8:31 AM 3 min read In This Article: MGRM -0.51% Award from Medical Tech...
Yahoo Finance Community
10/30
Comment
What I don't understand is why people hang around to bash a company. When I don't like a company, even if I invested in it previously, I sell my shares and move on. I might look in on it from time to time just to see what's happening with it, but I certainly don't comment on it....
Votes:
3
0
Yahoo Finance News
10/31
MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.
MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission. Zacks Small Cap Research Thu, Oct 31, 2024, 10:18 AM 3 min read In...
Yahoo Finance Community
11/01
Comment
I shared example emails with the SEC that I’d sent to Monogram, highlighting my concerns multiple times. After more than seven years and repeated mishandlings—starting with the very first share transfer issues—I’m determined to see this through to a logical conclusion. I'm looking for accountability from Monogram, specifically from those responsible—Dr. Unis and his incompetent CEO....
Votes:
1
0
Yahoo Finance Community
11/04
Comment
The FDA provided a response giving MGRM 180 days to respond to their issues. My understanding is this is for a SEMI-ACTIVE system. in parallel, MGRM is planning a separate clinical trial in India that will FIRST need approval from the Indian Regulatory Authority. I am assuming this is for the ACTIVE system. It would appear MGRM is setting up to provide another 510 submission to the FDA sometime in the latter part of 2025 for its active system. This submission will include data for the OUS clinical trial for 92 patients in Imdia. Could someone please explain what are the main differences between the ACTIVE and SEMI-ACTIVE systems?...
Yahoo Finance Community
11/04
Comment
I will point out recent misleading statements from Monogram, which indicate either they provided false information before or are now creating confusion.The CEO repeatedly stated they were submitting a 510(k) application for the semi-active system, with clinical trials to follow if required, and that any necessary information could be supplemented later. However, new information now indicates that the clinical trial is for the active system. This raises questions: If they never intended to conduct a semi-active system trial, how did they plan to supplement that information to the FDA? Has the semi-active system been abandoned? Did the FDA require clinical trial data, and if so, how does Monogram plan to provide it?Are they planning to commercialize the semi-active system? This is unclear because no mention of it appeared in the materials presented at the LD Micro Main Event XVII (October 29, 2024). The only relevant note is the planned commercial …...
Votes:
1
0
Yahoo Finance Community
11/07
Comment
Just watched the LD Micro Main Event, and the illustrations are impressive. Monogram is setting up their patent portfolio in a very aggressive way, with 23+ patents, and owning the active/autonomous saw-cutting space, whereby anyone copying robot cuts with a saw attached to a robot will infringe on their IP. That's gonna be HUGE....
Votes:
4
0
Yahoo Finance Community
11/07
Comment
The FDA's AIR main issues were: needing more high BMI patients (test cadavers were low BMI), establishing learning curve of robot with users of novus-robotic experience ("no experience with robots"), and additional tests to address cut accuracy methodology according to FDA-stringency. They currently have no debt....
Votes:
2
0
Yahoo Finance News
11/12
Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time
Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time Monogram Technologies Inc. Tue, Nov 12, 2024, 8:31 AM 4 min read In Thi...
Yahoo Finance Community
11/13
Comment
Hopefully management will provide a little more insight regarding the planned clinical trial in India. Is FDA approval on the semi-active robot a pre-requisite before the clinical trial in India can proceed? It is hard for me to imagine that the clinical trial will proceed without this approval....
Yahoo Finance Community
11/13
Comment
Just wait and watch—the CEO will keep making excuses. Management has no real interest in securing FDA approval, as it would threaten their comfortable paychecks. They're perfectly content to keep raising funds, draining investors' hard-earned money while delivering nothing in return. If they did pursue FDA approval, they’d be forced to come up with a commercialization strategy—something they obviously lack....
Votes:
2
0
Yahoo Finance Community
11/14
Comment
I see the strategy now—they’ll drive the stock price down to $1.50–$1.75 so that ‘someone’ can buy in bulk, then push it back up for that ‘someone’ to make millions. Unless we collectively demand accountability, this shameless team won’t take any real action. They have no incentive to change; they’re getting their paychecks, so why bother doing anything ?...
Votes:
3
1
Yahoo Finance News
11/14
Monogram Technologies Reports Third Quarter 2024 Financial Results
Monogram Technologies Reports Third Quarter 2024 Financial Results Monogram Technologies Inc. Thu, Nov 14, 2024, 4:05 PM 12 min read In This Article: MGRM -0.51% Closed an Upsized and Oversubscribed $...
Yahoo Finance Community
11/14
Comment
Ah, a press release masterpiece! And yet, the stock still sits proudly at $2 (after hours). Just the kind of market excitement everyone was hoping for, right?So, when’s Ben planning to step down and actually take responsibility? If you all want to see a return on your investment, start pushing for it....
Quantexa News
11/14
Monogram Orthopaedics Advances with FDA Filing and Partnerships
The latest announcement is out from Monogram Orthopaedics Inc ( (MGRM) Monogram Technologies, an AI-driven robotics company, reported significant progress in the third quarter of 2024, including a $1...
Yahoo Finance Community
11/15
Comment
Everyone, if you want to protect your hard-earned money, it's time to demand accountability and call for the CEO’s resignation. As investors, let’s take action—reach out to Monogram, send emails, and make our voices heard. We need a CEO with real experience, someone who knows how to deliver results instead of just collecting paychecks.Where else can someone get paid for doing so little? If we performed like this in our jobs, we’d have been fired long ago. Let’s push for leadership that values progress and transparency....
Votes:
2
0
Yahoo Finance Community
11/15
Comment
Master Service Agreement was signed between Sponsor and "Omitted" on May 9 & 10th. May, June, July, Aug, Sept, Oct, to now Nov. That's 7 months of behind-the-scenes progress that we learn after the fact through SEC filings. We don't know how far along the clinical trials are, but 1) if a 3-month leeway is given for gaining regulatory approvals since May 10th, we can anticipate the OUS started around Sept, then 2) (predicting) 3 months of testing and operations, would end in Nov, with 3) 3 months of followup and final Results available Feb 2025 or sooner. The 180-day AIR would expire March 19, 2025, which should be plenty of time to fully respond, and thus, launch the commercialization efforts upon FDA decision. NFA...
Votes:
1
0
Yahoo Finance Community
11/15
Comment
Did you notice that the piece in Bezinga was sponsored? Who do you think sponsored it?Do the surgeons excited about 3D printed joint replacements realize that custom implants have been around for 35 years and that CFMS burned $600 million proving that the market won't pay for them?DePuy Actis hips have a revision rate of 1.7% at 7 years in the American Joint Registry. Anyone saying they can beat that might need to make a few implants and provide some evidence before the market believes them.But hey, MGRM was named "orthopedic joint replacement company of the year" by someone despite never having sold one or implanting a single joint replacement in a single living human. Click on the link to that and see if you can get to the bottom of that accolade....
Yahoo Finance News
11/17
Will Monogram Technologies (NASDAQ:MGRM) Spend Its Cash Wisely?
Will Monogram Technologies (NASDAQ:MGRM) Spend Its Cash Wisely? editorial-team@simplywallst.com (Simply Wall St) Sun, Nov 17, 2024, 9:33 AM 4 min read In This Article: MGRM -0.51% Just because a busin...
Yahoo Finance Community
11/18
Comment
Good morning! I have an email confirmation from Monogram stating that they have NOT initiated clinical trials. In fact, they only filed for clinical trial approval in late October or early November. Until that approval is granted, the trials cannot begin....
Votes:
1
0
Yahoo Finance Community
11/18
Comment
See biscuitpants posts on the other message st...twits...my interpretation of the info shared is that MGRM would need FDA approval on the sem-active robot (hopefully in the next couple months) before a clinical trial can begin in India. You are encouraged to do your own research related to getting approval for medical devices in India....
Yahoo Finance Community
11/18
Comment
Below is the response to my email from Monogram dated October 5th. It represents yet another inconsistency. According to the email, the FDA is suggesting the need for clinical trial data, while the management team has publicly stated that no clinical data is required. So, who’s telling the truth, and who’s providing misleading statements:"We do not have clinical trial data since we did not perform any clinical trials, so it would not be new data. The FDA is suggesting clinical trial data would be helpful, so we are moving forward with obtaining clearance to perform those trials. We did not submit for clinical trials. As the email states, we hope to submit soon and obtain clearance by Q1 2025."...
Votes:
2
0
Yahoo Finance Community
11/19
Comment
Based on the evidence I’ve gathered (including emails from Monogram clearly stating that the FDA suggested clinical data for the semi-active system and public statements), here’s what I conclude. The repeated pattern of hiding information and making misleading statements raises serious ethical questions—how is this not criminal?Management initially assumed that transitioning to the semi-active system would not require a clinical trial. However, in the FDA follow-up on September 30th, it became clear that clinical trial data would indeed be necessary, catching Monogram completely off guard. In response, they hastily filed for clinical trial approval. It also seems they began questioning their decision to pursue the semi-active system if it required clinical trials, leading them to shift their narrative toward a fully active system instead.Now, they face a significant uphill battle—not only securing approval for the clinical trial but also completing the trials and submitting the required data to the FDA. …...
Yahoo Finance Community
11/19
Comment
Speculation...I believe MGRM wanted FDA approval on the semi-active surgical robot as it was believed seeking approval on the next-gen (includes MVision) surgical robot would be a much tougher nut to crack/hurdle. It is believed MGRM ultimate end-game is to seek FDA approval on the next-gen surgical robot....MGRM will seek FDA approval after the OUS clinical trial in India...this submission should prove to have a much greater chance of FDA approval, as the FDA approval on the semi-active robot would have already taken place. The 2nd FDA submission would primarily focus on the Mvision navigational system. Time will tell...
Votes:
3
0
Yahoo Finance Community
11/19
Comment
OUS clinical trials, soft approval to import the unit for training purposes, Approval is still in process. No specific dates. AIR response: 40 pages, very detailed response planned to submit this week with the proposed testing to address the questions and comments raised by FDA, after which FDA would have 21 days to respond....
Votes:
2
0
Quantexa News
11/20
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q3 2024 Earnings Call Transcript
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q3 2024 Earnings Call Transcript November 19, 2024 Operator: Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Busi...
Yahoo Finance Community
11/20
Comment
No offense RI, but first of all, you openly admit to not doing any research into your investment, and second, you are now making claims to have knowledge on how long it should take to a make robotics system. Who's fault is it that you put your money here? The fact you are leaving is a personal choice ,so why share this information unless you are trying to influence. There are always complainers that linger in the different chat rooms long after they have sold off. Hopefully, you are not one of them. Better luck on your next investment....
Yahoo Finance Community
11/20
Comment
An email from Ben S. (CEO) dated October 20, 2023, at 8:03 AM—exactly 1 year and 1 month ago—reads almost identical to the Q3 report released on November 19, 2024 (yesterday). How is this not a scam? Where is the progress over the past year, during which he and his team pocketed the majority of the money while investors were left mislead & deceived? No wonder, investors are leaving.I’m sharing a quoted paragraph from the email."Monogram now employs 27 full-time employees and approximately 30 contractors working flat out to hit our objectives. Monogram recently received FDA Clearance for Export with a Certificate to Foreign Government/Certificate of Exportability that advances us on our path to launch outside the US for a Pilot Program with a Global Distributor. The system is performing at a high level, testing with pilot program implants is on schedule, and we remain on track to ship on …...
Yahoo Finance Community
11/21
Comment
CEO from Q3 CC ... "We expect during that meeting (the upcoming planned December FDA meeting) we will get a lot more clarity on whether our proposed testing plan will fully address all the FDA questions and that we're thinking this will be a really critical moment for the company in terms of derisking the application. Obviously NOTHING'S GUARANTEED, but it will certainly be helpful to have a conversation with the FDA for more clarity."...
Votes:
2
0
Yahoo Finance Community
11/21
Comment
Comment n last post: The hidden message in NOTHING'S GUARANTEED??? I think that the CEO believes that he EXPECTS the FDA to take a favorable position on MGRM's proposed testing plan.....see meaning of NOTHING'S GUARANTEED below: Nothing is guaranteed" essentially means that you can't be certain about any outcome in life, and that UNEXPECTED events can happen at any time, so you shouldn't take anything for granted....
Votes:
1
1
Yahoo Finance Community
11/21
Comment
How does this comment get rejected by Yahoo when it's clearly to inform how to educate oneself on investor acumen? When I said, "Tune in to conference calls, watch webinars, and look up SEC EDGAR Monogram" for latest updates and security filings....
Votes:
1
0
Yahoo Finance Community
11/27
Comment
Looks like the CFO Noel Knape purchased a bunch of shares this week on 11/25/24 with a recent SEC filing acquiring 288,461 shares. This looks to be the first purchase by an insider I’ve seen since Monogram went public. Huge vote of confidence with such a large quantity purchased in my opinion....
Quantexa News
11/29
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decrease in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 179,400 shares, a decline of 30.1...
Quantexa News
11/29
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decrease in Short Interest
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest tota...
Quantexa News
11/30
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decrease in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 179,400 shares, a decline of 30.1...
Yahoo Finance News
12/02
Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million
Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million Monogram Technologies Inc. Mon, Dec 2, 2024, 4:05 PM 3 min read I...
Yahoo Finance Community
12/05
Comment
It’s beyond frustrating to see Monogram’s leadership bungle basic milestones while the stock continues to languish. Within a week of insider stock purchases—clearly a move to artificially inflate confidence—the CEO conveniently publishes a fluff piece to prop up the stock price. Yet, there’s still no clear answer about the following:AIR report ( which he bragged about 40+ pages response )—has it been submitted? Have the products even shipped to India (given they got the soft approval )? What about meeting with FDA in Dec regarding AIR?Clinical trial approval from India ?? The timing of the so-called “soft approval” on the 19th Nov, coinciding with their earnings call, seems far too convenient to be legitimate....
Yahoo Finance Community
12/09
Comment
Either way, it's a penny stock and shorts are waiting to hammer it down after any type of increase. That's life. So trade cautiously, know when to make moves that suits you. And if the saying "Buy the rumor, sell the news" helps you then so be it. NFA. Not anything really. Just typing....
Quantexa News
12/12
FY2024 Earnings Estimate for MGRM Issued By Roth Capital
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Free Report ) – Equities researchers at Roth Capital issued their FY2024 earnings estimates for shares of Monogram Orthopaedics in a research note issued on...
Yahoo Finance Community
12/17
Comment
In most places, those who do the actual work understand that the only way to earn a paycheck is through hard work and delivering results. If you’ve taken money from someone, the responsibility is to work twice as hard to return that trust.Monogram stands out as an exception—where management misleads, fails to deliver, delays progress, yet still collects their paychecks....unbelievable....
Yahoo Finance Community
12/19
Comment
The robot MUST transition out of the lab and be tested on real people to demonstrate its benefits. We’ve been informed that there’s no active development underway, verification and validation (V&V) are complete, and the system is ISO certified. However, as investors, we’re bearing a significant cost—$40K per day, totaling $1.2 million each month....
Yahoo Finance Community
12/23
Comment
The FDA is requesting additional information to include issue-specific items such as high BMI patients, training of novice user operation of robot and the active cut methodology, which can be ascertained through the clinical trials. These items have been outlined by the plan which was considered and reviewed by the FDA....
Votes:
1
0
Yahoo Finance Community
12/27
Comment
The robot MUST transition out of the lab and be tested on real people to demonstrate its benefits. We’ve been informed that there’s no active development underway, verification and validation (V&V) are complete, and the system is ISO certified. However, as investors, we’re still bearing a significant cost—$40K per day, totaling $1.2 million each month ....WHY ?...
Votes:
1
0
Yahoo Finance Community
12/30
Comment
Will MGRM miss the stated Shalby deadline? One was announced then rescinded. If we are going to hit it, people who subscribed to the most recent funding may want to turn their preferred shares into plain shares before this happens since the company can call preferred shares at $4.50.August 12, 2024 Initial Shalby announcementAugust 14, 2024 Shalby mentioned second quarter resultsOctober 2, 2024 Shalby expected approval statement - Obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals, with clearance expected in early Q1 2025.December 2, 2024 Shalby statement downgraded by removing expected clearance - Seek to obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals.December 18, 2024 Shalby downgraded statement repeated....
Yahoo Finance Community
12/31
Comment
This company is headed towards great things. Vying to own the "active/autonomous" cutting space. Securing a line of patents within that spectrum will invariably canonize MGRM as a pioneer in that space and be a huge asset to both the evolution of orthopedic care and efficiency of its applications and methods. Just waiting on FDA to give clearance on the semi-active system for the 510(k) app for the mBos TKA system. My guess is that it is currently being reviewed by FDA, since MGRM said they would respond to the AR after the Dec 17 call, and the updated application is getting shuffled around to the right hands....
Votes:
3
0
Yahoo Finance Community
12/31
Comment
Who flipped the narrative from "Fully Autonomous System" to "Semi-Active System," only to flip it back to "Fully Autonomous System"? That would be the incompetent CEO, Ben S. He did it to raise money, and now we’re stuck in a mess. We’re looking at two 510(k) applications—one supposedly filed in July and another pending after clinical trials.Who promised clinical trials in 2023 and shipping robots? Here we are, still waiting for those clinical trials because there’s no approval in sight.What we need is a leader who is focused, knows what they’re doing, and can get it done quickly. Instead, we’re burning time and money, while investors continue to suffer losses....
Votes:
1
0
Yahoo Finance Community
01/02
Comment
@FriendoI agree. I've set February 15th as the deadline for selling my stocks. If Monogram doesn’t take action in the next 4-6 weeks, I’ll be selling all my shares. Honestly, we should all consider doing the same—maybe that’s the only way they’ll finally get the message....
Yahoo Finance Community
01/02
Comment
With MGRM's technology as it is, this won't be a simple approval of an equivalent device. It will mark the ushering in of a powerful and multi-applicational robot that will advance orthopedic medicine. The "haptic" bone-cutting world will get a very strong shoulder-check for being antiquated and imprecise and, further, strenuous upon the surgeon....
Votes:
1
0
Yahoo Finance Community
01/03
Comment
@Thomas RReach out to Monogram, SEC, and Shalby. Make your voice heard! Demand answers—why isn’t the robot coming out of the lab? Why aren’t they delivering results? This is your hard-earned money, and you deserve accountability for every cent of it. Don’t let them take you for granted!...
Votes:
1
0
Yahoo Finance Community
01/06
Comment
@William @thomas Ah, sounds like a familiar tale—you bought at $7.59, and of course, the stock’s been on a steady downhill stroll ever since. I’ve been in this for seven years, and let me tell you, waiting has become my second career. Meanwhile, management? Oh, they’re out there doing the real work—cashing paychecks and delivering a whole lot of nothing.Here’s what I’ve learned over the years: don’t just sit back and watch. Reach out to Monogram, SEC, and Shalby. Demand answers. After all, someone’s got to hold them accountable, right?...
Yahoo Finance Community
01/10
Comment
@Friendo As investors, we’re paying $40k per day—amounting to $1.2 million per month. It seems the focus is more on collecting those paychecks, with an approach that feels like delaying progress while securing as much as possible before moving on to other opportunities....
Quantexa News
01/26
Barclays PLC Invests $29,000 in Monogram Orthopaedics, Inc. (NASDAQ:MGRM)
Barclays PLC acquired a new stake in Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Free Report ) in the third quarter, according to the company in its most recent filing with the Securities & Exchange C...
Quantexa News
01/29
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Down 42.8% in January
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 129,...
Quantexa News
01/29
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Down 42.8% in January
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 129,000 shares,...
Yahoo Finance Community
01/30
Comment
I held this stock since inception and it's slow as a tortoise. So, I sold and am getting into crypto - XRP, HBAR, and XLM -with great growth and no capital gains tax. Open a Coinbase account_link your bank, and start buying -it's very simple. You're welcome :)...
Quantexa News
01/30
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Short Interest Down 42.8% in January
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 129,000 shares,...
Yahoo Finance Community
02/06
Comment
Why don’t certain people cease with the criticism and let the company do their job. Hum🤔 let me see now, do I want this company focusing on petty people on this message board or do I want them focusing on taking care of business so we can make some money. Boy, that’s a tough one....
Votes:
6
1
Yahoo Finance Community
02/07
Comment
So this is a razor and razorblade model right? Monogram was going to build a custom implant for each patient - a model that has been tried for over 3 decades with no real uptake.No custom implants yet. Not a single one implanted.Meanwhile there are at least 15 knee robots competing for attention and dollars. One has maybe 60% of the market and the next 3 are being given away for free by credible companies that control 85% of the market.None of the 8 that follow are selling for much if any money and selling things costs a lot of money.Fanboys gotta fan though right?...
Yahoo Finance Community
02/14
Comment
@Darin It really doesn’t matter what anyone says on this forum or how much money people are making by shorting or day trading here. What truly matters is how Monogram is delivering—and we all know the answer to that. Some are just more vocal than others, but the reality is written on the wall.Personally, I’m very happy that at least someone is making money—at least someone is! But let’s be real, they’re not making money because Monogram is delivering. They’re making money because Monogram is not delivering. 😆...
Votes:
1
1
Yahoo Finance Community
02/14
Comment
There are some here that bought in very low $2 and lower. Trimming is what smart investors do after making 25% on their money. You stated earlier that you once were up 100k and gave most or all back. Why did you erase that part of our conversation?...
Votes:
1
1
Yahoo Finance Community
02/14
Comment
This chatroom was designed for shareholders and new potential investors to have constructive conversations ,not to be used for a sounding board for assumption and accusations with no substantial facts to back up statements.So yes it does matter what's written here. Here a fact ,the company openly said they are having a problem with FDA, and yes, they also stated that they were sending a robot to India. Just because we haven't seen an update doesn't mean the company is sitting on their hands. I can't find documentation stating that the robot was or wasn't sent. Hopefully, updates happen soon so we can all get the true answers and stop the endless repetitive nonsensical posting based on little or no facts. Have a great weekend!!...
Votes:
2
1
Quantexa News
02/15
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Drop in Short Interest
Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling...
Quantexa News
02/16
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decline in Short Interest
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 116,700 shares, a de...
Quantexa News
02/16
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Sees Significant Decline in Short Interest
Monogram Orthopaedics, Inc. ( NASDAQ:MGRM – Get Free Report ) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 116,700 shares, a decline o...
Yahoo Finance Community
02/18
Comment
Let’s put it this way, Ben S has never been through an FDA approval process so he is going to have continuous delays because he is unprepared for everything that is needed to get the job done. This task should have been preformed by someone who has multiple experiences with going through the process to avoid delays and burning through excess cash. Granted the process is not easy that’s why you need someone who has been there and done that. Delays only give the competition time to play catch up and plan their attack given the resources they have over you. There is the possibility that the real owners of the technology will pivot and bring a new CEO in to finish the job in a timely fashion. I’m giving him one more month before start to petition for a new CEO if he doesn’t get his act together....
Votes:
2
0
Quantexa News
02/20
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 2.9% – Here's Why
Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) traded up 2.9% during mid-day trading on Wednesday . The stock traded as high as $2.54 and last traded at $2.49. 56,315 shares traded hands...
Quantexa News
02/20
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 2.9% - Here's Why
Shares of Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Get Free Report) shot up 2.9% during mid-day trading on Wednesday . The company traded as high as $2.54 and last traded at $2.49. 56,315 shares tra...
Quantexa News
02/20
Monogram Orthopaedics (NASDAQ:MGRM) Shares Up 2.9% – Here’s Why
Shares of Monogram Orthopaedics, Inc. (NASDAQ:MGRM – Get Free Report) shot up 2.9% during mid-day trading on Wednesday . The company traded as high as $2.54 and last traded at $2.49. 56,315 shares tra...
Yahoo Finance News
02/27
MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Pr...
Yahoo Finance News
02/27
Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025...
Yahoo Finance News
03/12
Monogram Technologies Reports Full Year 2024 Financial Results
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Monogram Technologies Reports Full Year 2024 Financial Results ACCESS Newswire · Monogram Technologies Inc. Monogram...
Yahoo Finance News
03/12
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results ACCESS Newswire · Monogram Technologies I...
Quantexa News
03/13
Analysts Offer Insights on Healthcare Companies: Monogram Orthopaedics Inc (MGRM) and Vivani Medical (VANI)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monogram Orthopaedics Inc ( MGRM – Research Report ) and Vivani Medical ( VANI – Research Report ) with b...
Quantexa News
03/13
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q4 2024 Earnings Call Transcript
Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q4 2024 Earnings Call Transcript March 12, 2025 Larry Holub: Good afternoon everyone. I’m Larry Holub, Director at MZ North America, and would like to welcom...
Yahoo Finance News
03/13
MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results Zacks Small Cap Research Thu, Mar 13, 202...
Quantexa News
03/13
Monogram Orthopaedics Earnings Call: Balancing Innovation and Regulatory Challenges
Monogram Orthopaedics Inc ((MGRM)) has held its Q4 earnings call. Read on for the main highlights of the call. Monogram Orthopaedics Inc. Earnings Call: A Balanced Outlook Amidst Technological Stride...
